Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
1.98 USD -7.04% Intraday chart for Immix Biopharma, Inc. -2.94% -71.39%
05-10 Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation CI
05-09 Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial
Immix Biopharma Proposes Stock Offering; Shares Slump
Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
GNW-Adhoc: Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht
Immix Biopharma Says FDA Clears Investigational New Drug Application for NXC-201; Shares Fall
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Immix Biopharma, Inc. Announces Complete Response in 9Th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial At IMS 20Th Annual Meeting
Top Midday Gainers
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
Immix Biopharma Files Registration Statement on Behalf of Selling Stockholder
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. News Immix Biopharma, Inc.
  5. Other languages